FAS and ovarian cancer: To determine if FasTr or Fas-IFP T cells can lyse human ovarian cancer cells better than TCR530 T cells, T cells expressing an irrelevant TCR or T cells expressing TCR530 with or without FasTr or a Fas-4-1BB IFP were co-cultured with OVCAR3 tumor cells 155 hours.